Literature DB >> 17409902

Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging.

Jeremy J Erasmus1, Reginald F Munden, Mylene T Truong, Jeremy J Ho, Wayne L Hofstetter, Homer A Macapinlac, Arlene M Correa, Tsung-Teh Wu, John F Bruzzi, Edith M Marom, Bradley S Sabloff, Jaffer A Ajani, Ritsuko Komaki, Zhongxing Liao, Jeffrey H Lee, Norio Fukami, Robert Bresalier, Stephen G Swisher.   

Abstract

HYPOTHESIS: Positron emission tomography can be useful in predicting response of esophageal cancer after preoperative chemo-radiation therapy (CRT). We evaluated the use of integrated computed tomography (CT)-PET among patients with esophageal cancer being considered for resection after CRT.
METHODS: Three reviewers blinded to clinical and pathologic staging retrospectively reviewed the CT-PET scans of patients with esophageal cancer after preoperative CRT who underwent esophagectomy. [F]-fluoro-2-deoxy-D-glucose uptake for residual malignancy was determined by visual analysis and semi-quantitatively when standardized uptake value (SUV) was > or =4.
RESULTS: Forty-two patients underwent esophageal resection. Using visual analysis, CT-PET had a sensitivity of 47% and specificity of 58% in detecting residual malignancy. Using semi-quantitative analysis, 19 patients had a SUV > or =4 in the region of the primary esophageal tumor and were interpreted as having residual malignancy (sensitivity 43%, specificity 50%). Of these 19, six had complete pathologic response to CRT. These false-positive results, due to therapy-induced ulceration detected at endoscopy, limit the use of CT-PET alone in detecting residual malignancy. Similarly, sensitivity (25%) and specificity (73%) of endoscopy/biopsy in detecting residual malignancy were poor. However, the accuracy of CT-PET in detecting residual malignancy was improved when combined with endoscopic findings. In the absence of ulceration at endoscopy, 8 of 8 patients with SUV > or =4 after chemo-radiation had residual malignancy at surgery.
CONCLUSIONS: CRT-induced ulceration results in false-positive results on CT-PET and precludes accurate detection of residual esophageal tumor. However, CT-PET in combination with endoscopy is useful in identifying patients with a high risk of residual tumor post-CRT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17409902

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  15 in total

1.  Positron emission tomography's changing significance in the treatment of esophageal cancer.

Authors:  Shane Hopkins; Gary Yang
Journal:  World J Gastrointest Oncol       Date:  2009-10-15

2.  Value of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in prediction of the overall survival of esophageal cancer patients treated with chemoradiotherapy.

Authors:  Yimin Li; Qin Lin; Zuoming Luo; Long Zhao; Luchao Zhu; Long Sun; Hua Wu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  Predicting response to chemoradiotherapy in rectal and oesophageal cancer with 18F-FDG: prognostic value and possible role in patient management.

Authors:  Elif Hindié; Christophe Hennequin; Jean-luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

4.  Prognostic and predictive values of interim 18F-FDG PET during neoadjuvant chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis.

Authors:  Sangwon Han; Yong-Il Kim; Sungmin Woo; Tae-Hyung Kim; Jin-Sook Ryu
Journal:  Ann Nucl Med       Date:  2021-01-20       Impact factor: 2.668

5.  Positron Emission Tomography's Utility in Esophageal Cancer Management.

Authors:  Shane Hopkins; Gary Y Yang
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

Review 6.  [Importance of PET in surgery of esophageal cancer].

Authors:  K Ott; T Schmidt; F Lordick; K Herrmann
Journal:  Chirurg       Date:  2014-06       Impact factor: 0.955

Review 7.  Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma.

Authors:  Kazuto Harada; Dilsa Mizrak Kaya; Anthony Lopez; Hideo Baba; Jaffer A Ajani
Journal:  Ann Transl Med       Date:  2018-02

8.  A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.

Authors:  Stephen G Swisher; Kathryn A Winter; Ritsuko U Komaki; Jaffer A Ajani; Tsung T Wu; Wayne L Hofstetter; Andre A Konski; Christopher G Willett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-18       Impact factor: 7.038

Review 9.  State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment.

Authors:  Jolinta Lin; Seth Kligerman; Rakhi Goel; Payam Sajedi; Mohan Suntharalingam; Michael D Chuong
Journal:  J Gastrointest Oncol       Date:  2015-02

Review 10.  The role of FDG-PET and staging laparoscopy in the management of patients with cancer of the esophagus or gastroesophageal junction.

Authors:  Harry H Yoon; Val J Lowe; Stephen D Cassivi; Yvonne Romero
Journal:  Gastroenterol Clin North Am       Date:  2009-03       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.